Despite FDA putting a second clinical hold on its anti-NGF candidate fasinumab, Regeneron Pharmaceuticals Inc. and partner Teva Pharmaceutical Industries Ltd., which signed on just last month, expect to move into Phase III with a refined indication and adjusted dosing.
The anti-nerve growth factor (NGF) class has been fraught with safety issues – the entire class was placed on clinical...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)